RxDoctor Payments Data

Stephanie Hawkins

Psychiatric/Mental Health · Morristown, TNNPI 1689338642

Payments from drug & device makers

$1,874in general payments, 2019–2025

Across 80 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Supernus Pharmaceuticals, Inc.$282
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$198
  • Alkermes, Inc.$160
  • Corium, LLC$158
  • Otsuka America Pharmaceutical, Inc.$103
  • plus $453 from 9 others

What the payments were for

  • Food & beverage$1,874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,874 in reported general payments places this provider in the 70th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,382
Medicare patients
19
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$41,200
RexultiBrexpiprazole15$22,515
VraylarCariprazine Hcl14$21,666
Fluphenazine Hcl12$3,006
Trazodone Hcl93$2,103
Duloxetine Hcl32$2,005
Paliperidone ErPaliperidone11$1,952
Vilazodone Hcl20$1,826
Buspirone Hcl102$1,734
Lurasidone Hcl24$1,645
Quetiapine Fumarate74$1,533
Hydroxyzine Hcl64$1,279
Bupropion XlBupropion Hcl51$1,187
Aripiprazole40$824
Ziprasidone Hcl13$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$93$41,20013 claims
Otsuka America Pharmaceutical, Inc.Rexulti$103$22,51515 claims
AbbVieVraylar$521$21,66614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Morristown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →